Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
24 Cards in this Set
- Front
- Back
|
Methotrexate
a.) brand b.) class c.) pregnancy category d.) place in therapy & why (2) e.) ADR (4) f.) dose route & frequency g.) monitor (2) |
Methotrexate
a.) rheumatrex b.) non-biologic DMARD c.) category X d.) first line because most predictable, best long term outcome e.) stomatitis, hepatotoxicity, GI, alopecia f.) po weekly g.) CBC & LFT |
|
|
Leflunomide
a.) brand b.) class c.) pregnancy category & INDICATION & population d.) ADR (4) --monitor-- e.) place in therapy f.) dose route & frequency g.) C/I (3) |
Leflunomide
a.) Arava b.) non-biologic DMARD c.) X; mod-severe RA, pts with renal disease d.) rash, alopecia, liver, GI --monitor: CBC & LFT e.) alternative is MTX doesn't work. Don't combo bc increase hepatotoxicity f.) po daily; loading dose increases response g.) obstructive biliary disease, live problems, rifampin therapy |
|
|
Hydroxychloroquin
a.) brand b.) class c.) indication & population d.) ADR (3) e.) Monitor f.) dose route & frequency |
Hydroxychloroquin
a.) Plaquenil b.) non-biologic DMARD c.) FIRST LINE early/mild RA; pt has liver disease & CBC problems d.) Renal toxicity, GI, eye problems e.) yearly eye exams g.) po BID |
|
|
Sulfasalazine
a.) brand b.) class c.) indication & population d.) ADR major (4) e.) dosing route & frequency f.) Monitor (2) g.) place in therapy |
Sulfasalazine
a.) azulfidine b.) non-biologic DMARD c.) FIRST LINE mild-mod, good for renal disease d.) skin turns yellow-orange, sulfa allergy, photosensitivity, GI e.) po daily f.) CBC &LFT g.) alternative for pregnancy pts (category B) |
|
|
Minocycline
a.) class b.) indication c.) frequency d.) ADR-general |
minocycline
a.) tetracycline antibiotic b.) very mild RA c.) daily d.) well tolerated |
|
|
Gold
a.) class b,) indication c.) place in therapy & why d.) route & frequency |
Gold
a.) DMARD b.) RA but not first line c.) rarely used b/c long onset (3-6 months) d.) IM weekly |
|
|
Azathioprine
a.) brand b.) class c.) indication & place in therapy d.) dose & frequency |
Azathioprine
a.) imuran b.) DMARD c.) RA; rarely used d.) po daily |
|
|
Cyclosporine
a.) class b.) indication c.) ADR (3) d.) route & frequency |
cyclosporine
a.) DMARD b.) RA, rarely used unless pt has hepatotoxicity c.) nephrotoxicity, anemia, hypertension d.) po daily |
|
|
Biologic DMARDs
a.) place in therapy b.) limitations (2) c.) monitor d.) recent concern (2) |
Biologic DMARDs
a.) first line for severe RA; 2nd or 3rd line for mild-moderate b.) cost, infection risk c.) pt should look for infection bc life-threatening d.) malignancy, worsening heart failure |
|
|
TNF Antagonists
a.) place in therapy b.) black box warning c.) screening |
TNF antagonists
a.) First line biologic DMARDs (severe RA) b.) infection risk c.) TB before treatment |
|
|
Etancercept
a.) brand b.) class c.) dosing mode d.) frequency e.) C/I |
Entanercept
a.) Enbrel b.) biologic DMARD; TNF blocker c.) subq; self-administer d.) weekly (twice) e.) mod-severe heart failure |
|
|
Infliximab
a.) brand b.) class c.) dosing mode d.) frequency e.) combo g.) C/I |
Infliximab
a.) remicaide b.) biologic dmard; TNF blocker c.) IV, in doctor's office d.) IV is 2 hours (unlike orencia/abatacept) at 0, 2, 6 weeks, then q 8 weeks e.) MTX, like rituxan & actemira g.) mod-severe heart failure |
|
|
Adalimumab
a.) brand b.) class c.) dosing mode d.) frequency |
Adalimumab
a.) Humira b.) biologic dmard, TNF blocker c.) subq d.) q other week |
|
|
Golimumab
a.) brand b.) class c.) dosing mode d.) frequency |
Golimumab
a.) simponi b.) biologic DMARD; TNF blocker c.) subq; self-administer d.) MONTHLY |
|
|
Certolizumab pegol
a.) brand b.) class c.) dosing mode d.) frequency |
certolizumab pegol
a.) cimzia b.) biologic DMARD; TNF blocker c.) subq injection d.) weeks 2 & 4, then q other week or q 4 weeks |
|
|
anakinra
a.) brand b.) class c.) dosing mode d.) frequency e.) limitations (2) |
anakinra
a.) kineret b.) IL-1 antagonist c.) subq, self-administer d.) daily e.) not as effective as biologics, limited data |
|
|
Rituximab
a.) brand b.) class c.) dosing mode d.) frequency e.) combo f.) black box warning (3) & pretreat |
Rituximab
a.) rituxan b.) anti-CD20 mab c.) IV d.) weeks e.) MTX like infliximab & tocilizumab f.) tumor lysis syndrome, fatal infusion rxns, severe mucocutaneous rxns; pre-treat with prednisone or diphenhydramine |
|
|
Abatacept
a.) brand b.) class c.) dosing mode & duration d.) frequency e.) prior treatment f.) ADR (3) |
abatacept
a.) orencia b.) selective co-stim modulator c.) IV, 30 min (unlike infliximab) d.) week 2 & 4; q 4 weeks e.) TB screen f.) lung problems, HA, Nausea |
|
|
Tocilizumab
a.) brand b.) class & prior c.) dosing mode & frequency d.) combo e.) ADR (4) f.) C/I (3) |
Tocilizumab
a.) actemra b.) humanized mab to IL-6 c.) IV/ weekly d.) MTX like (infliximab, rituximab) e.) BP, cholesterol, fungal infection, LFT f.) abnormal aminotransaminase, platelet, ANC |
|
|
Tofacitinib
a.) brand b.) class c.) dosing mode d.) frequency |
Tofacitinib
a.) xelijanz b.) janus kinase inhibitor c.) ORAL! d.) BID |
|
|
main non-biologic DMARDs (4)
1st line biologic DMARDs (5) |
non: methotrexate, sulfasalazine, hydroxychloroquine, leflunomide
bio: CAGE-I - certolizumab pegol, adalimumab, golimumab, etanercept, infliximab |
|
|
Biologic Dosing route & frequency
a.) certolizumab pegol b,) Adalimumab c.) Golimumab d.) Etanercept e.) Infliximab |
a.) cimzia: SQ/weekly
b.) humira: SQ/weekly c.) simponi: SQ/ MONTHLY d.) etanercept: SQ/weekly e.) remicaide: IV weekly |
|
|
non-biologic DMARD dosing route & frequency
a.) methotrexate b.) leflunomide c.) hydroxychloroquine d.) sulfasalazine |
a.) rheumatrex: PO/weekly
b.) arava: PO/ daily c.) plaquenil: PO/ daily d.) azulfidine: PO/ daily |
|
|
miscellaneous dosing route & frequency
a.) rituximab b.) anakinra c.) abatacept d.) tocilizumab e.) tofacitinib |
a.) rituxan: IV/weekly
b.) kineret: SQ/daily c.) orencia: IV/weekly d.) actemra: IV/ weekly e.) xelijanz: ORAL! |
